These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33347022)

  • 1. The Effect of Add-on Buprenorphine to Matrix Program in Reduction of Craving and Relapse Among People With Methamphetamine Use Disorder: A Randomized Controlled Trial.
    Kheirabadi GR; Bahrami M; Shariat A; Tarrahi M
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):45-48. PubMed ID: 33347022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Buprenorphine on Methamphetamine Cravings.
    Salehi M; Emadossadat A; Kheirabadi GR; Maracy MR; Sharbafchi MR
    J Clin Psychopharmacol; 2015 Dec; 35(6):724-7. PubMed ID: 26468683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder.
    Aryan N; Banafshe HR; Farnia V; Shakeri J; Alikhani M; Rahimi H; Sehat M; Mamsharifi P; Ghaderi A; Omidi A
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):72. PubMed ID: 32977820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study.
    Mousavi SG; Sharbafchi MR; Salehi M; Peykanpour M; Karimian Sichani N; Maracy M
    Arch Iran Med; 2015 Jan; 18(1):28-33. PubMed ID: 25556383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial.
    Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K
    Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial.
    Kheirabadi GR; Ghavami M; Maracy MR; Salehi M; Sharbafchi MR
    Adv Biomed Res; 2016; 5():149. PubMed ID: 27656618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
    Rezaei F; Emami M; Zahed S; Morabbi MJ; Farahzadi M; Akhondzadeh S
    Daru; 2015 Jan; 23(1):2. PubMed ID: 25588930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
    McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
    Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial.
    Farahzadi MH; Moazen-Zadeh E; Razaghi E; Zarrindast MR; Bidaki R; Akhondzadeh S
    J Psychopharmacol; 2019 Mar; 33(3):305-315. PubMed ID: 30526230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
    Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
    Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy.
    Rabiey A; Hassani-Abharian P; Farhad M; Moravveji AR; Akasheh G; Banafshe HR
    Arch Iran Med; 2019 Dec; 22(12):692-698. PubMed ID: 31823620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.
    Lim AC; Grodin EN; Green R; Venegas A; Meredith LR; Courtney KE; Moallem NR; Sayegh P; London ED; Ray LA
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):565-576. PubMed ID: 32343625
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of methamphetamine abuse treatment: Predictors of treatment completion and comparison of two residential treatment programs.
    Kamp F; Proebstl L; Hager L; Schreiber A; Riebschläger M; Neumann S; Straif M; Schacht-Jablonowsky M; Manz K; Soyka M; Koller G
    Drug Alcohol Depend; 2019 Aug; 201():8-15. PubMed ID: 31154239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The exploration of optimized protocol for repetitive transcranial magnetic stimulation in the treatment of methamphetamine use disorder: A randomized sham-controlled study.
    Chen T; Su H; Li R; Jiang H; Li X; Wu Q; Tan H; Zhang J; Zhong N; Du J; Gu H; Zhao M
    EBioMedicine; 2020 Oct; 60():103027. PubMed ID: 32980696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder.
    Mojtabai R; Susukida R; Farokhnia M; Nguyen TQ; Dunn KE; Amin-Esmaeili M
    Addiction; 2024 Oct; 119(10):1803-1812. PubMed ID: 38984671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
    Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
    Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users.
    Hartwell EE; Moallem NR; Courtney KE; Glasner-Edwards S; Ray LA
    J Addict Med; 2016; 10(6):395-401. PubMed ID: 27504928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.